Ubs Group Ag Ardelyx, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Ardelyx, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 522,422 shares of ARDX stock, worth $2.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

522,422

Previous 474,437 10.11%

Holding current value

$2.66 Million

Previous $3.52 Million 2.39%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$5.28 - $7.57 $253,360 - $363,246	47,985 Added 10.11%	522,422 $3.6 Million
Q2 2024 Aug 13, 2024	SELL	$5.89 - $9.31 $2.42 Million - $3.82 Million	-410,066 Reduced 46.36%	474,437 $3.52 Million
Q1 2024 May 13, 2024	BUY	$6.05 - $9.74 $1.73 Million - $2.78 Million	285,853 Added 47.75%	884,503 $6.46 Million
Q4 2023 Feb 09, 2024	BUY	$3.29 - $6.64 $1.24 Million - $2.5 Million	376,294 Added 169.23%	598,650 $3.71 Million
Q3 2023 Nov 09, 2023	SELL	$3.3 - $4.83 $1.2 Million - $1.76 Million	-363,759 Reduced 62.06%	222,356 $907,000
Q2 2023 Aug 11, 2023	BUY	$3.23 - $4.95 $26,056 - $39,931	8,067 Added 1.4%	586,115 $1.99 Million
Q1 2023 May 12, 2023	BUY	$2.68 - $4.79 $1.21 Million - $2.16 Million	450,996 Added 354.97%	578,048 $2.77 Million
Q4 2022 Feb 08, 2023	BUY	$1.22 - $2.85 $149,147 - $348,418	122,252 Added 2546.92%	127,052 $362,000
Q2 2022 Aug 10, 2022	SELL	$0.51 - $1.17 $52 - $120	-103 Reduced 2.1%	4,800 $3,000
Q1 2022 May 16, 2022	SELL	$0.65 - $1.18 $19,812 - $35,967	-30,481 Reduced 86.14%	4,903 $5,000
Q4 2021 Feb 14, 2022	BUY	$0.86 - $1.7 $23,804 - $47,056	27,680 Added 359.29%	35,384 $39,000
Q3 2021 Nov 15, 2021	SELL	$1.27 - $8.17 $51,341 - $330,280	-40,426 Reduced 83.99%	7,704 $10,000
Q2 2021 Aug 13, 2021	SELL	$6.55 - $8.98 $322,076 - $441,564	-49,172 Reduced 50.54%	48,130 $365,000
Q1 2021 May 12, 2021	BUY	$6.1 - $7.69 $515,431 - $649,781	84,497 Added 659.88%	97,302 $644,000
Q4 2020 Feb 11, 2021	BUY	$5.05 - $7.1 $1,757 - $2,470	348 Added 2.79%	12,805 $83,000
Q3 2020 Nov 12, 2020	BUY	$5.25 - $7.08 $2,467 - $3,327	470 Added 3.92%	12,457 $66,000
Q2 2020 Jul 31, 2020	SELL	$5.37 - $8.11 $98,351 - $148,534	-18,315 Reduced 60.44%	11,987 $83,000
Q1 2020 May 01, 2020	SELL	$4.35 - $8.79 $81,632 - $164,953	-18,766 Reduced 38.24%	30,302 $172,000
Q4 2019 Feb 14, 2020	BUY	$4.23 - $8.29 $51,614 - $101,154	12,202 Added 33.1%	49,068 $368,000
Q3 2019 Nov 14, 2019	BUY	$2.15 - $6.28 $51,342 - $149,966	23,880 Added 183.89%	36,866 $173,000
Q2 2019 Aug 14, 2019	BUY	$2.49 - $3.73 $24,865 - $37,247	9,986 Added 332.87%	12,986 $35,000
Q1 2019 May 14, 2019	SELL	$1.88 - $3.35 $31,952 - $56,936	-16,996 Reduced 85.0%	3,000 $8,000
Q4 2018 Feb 14, 2019	BUY	$1.66 - $4.16 $27,200 - $68,165	16,386 Added 453.91%	19,996 $35,000
Q3 2018 Nov 14, 2018	SELL	$3.75 - $4.65 $4,462 - $5,533	-1,190 Reduced 24.79%	3,610 $16,000
Q2 2018 Aug 14, 2018	SELL	$3.7 - $5.8 $18,500 - $29,000	-5,000 Reduced 51.02%	4,800 $18,000
Q1 2018 May 15, 2018	SELL	$5.05 - $7.9 $4,040 - $6,320	-800 Reduced 7.55%	9,800 $49,000
Q4 2017 Feb 14, 2018	SELL	$4.85 - $7.8 $6,363 - $10,233	-1,312 Reduced 11.01%	10,600 $70,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $16,717 - $21,905	3,843 Added 47.63%	11,912 $67,000
Q2 2017 Aug 14, 2017	BUY	N/A	5,155 Added 176.9%	8,069 $41,000
Q1 2017 Nov 14, 2017	BUY	N/A	2,914	2,914 $36,000

Others Institutions Holding ARDX

# of Institutions

218

Shares Held

141M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $787M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account